PMN442 / ProMIS Neurosci - LARVOL DELTA

Key Pipeline Programs (GlobeNewswire) - "PMN267 is a humanized IgG1 antibody directed against toxic misfolded TDP-43 as a potential therapeutic target for ALS and is ready to progress to IND-enabling studies....PMN442 is a humanized IgG1 antibody and is ProMIS’s lead candidate for PD, MSA and other synucleinopathies based on its selective binding and protective activity against pathogenic forms of alpha-synuclein and is ready to progress to IND-enabling studies."

Preclinical • Amyotrophic Lateral Sclerosis • Multiple System Atrophy • Parkinson's Disease • Tauopathies And Synucleinopathies

ProMIS Neurosciences Announces Second Quarter 2021 Results (GlobeNewswire) - “In Alzheimer’s we will restart IND enabling work for PMN310, our antibody highly selective for toxic oligomers of amyloid. That selectivity may prove to give PMN310 significant competitive advantages in safety and efficacy over products from Biogen, Lilly, and Eisai that appear to provide benefit slowing the progression of Alzheimer’s disease....We will also further advance our alpha-synuclein program with further in vivo and in vitro validation, targeting diseases like Parkinson’s disease and Multiple System Atrophy.”

Preclinical • Alzheimer's Disease • CNS Disorders • Multiple System Atrophy • Parkinson's Disease